Carisoprodol, Phenytoin and Fosphenytoin Articles and Methods
A method of using carisoprodol, phenytoin or fosphenytoin comprises informing a user that co-administration of carisoprodol with phenytoin or fosphenytoin results in an increase in free phenytoin blood levels, a decrease in total phenytoin levels, or both. In another embodiment, a method of using carisoprodol, phenytoin or fosphenytoin comprises informing a user that when co-administering carisoprodol with phenytoin or fosphenytoin, the level of free phenytoin in a patient serum should be monitored, the level of total phenytoin should be monitored, or both. Also included are methods and articles of manufacture.
1 . A method of treating a patient in need of a skeletal muscle relaxant, comprising:
administering to a patient in need thereof a composition comprising carisoprodol, and
providing to the patient and/or a medical care worker published material providing information that when co-administering carisoprodol with phenytoin or fosphenytoin, the level of free phenytoin in a patient serum sample should be monitored.
2 . The method of claim 1 , wherein the information provides that the level of free phenytoin in the patient serum is measured once every 7 to 14 days.
3 . The method of claim 1 , further comprising determining if the patient is also co-administered phenytoin or fosphenytoin with the carisoprodol.
4 . The method of claim 2 , further comprising monitoring the free phenytoin concentration in a serum sample from the patient when the patient is co-administered phenytoin or fosphenytoin with the carisoprodol.
5 . The method of claim 1 , wherein the published material includes information that single-dose, co-administration of phenytoin and carisoprodol resulted in a 14% increase in the C max for free phenytoin and an 8% increase in the AUC 0-t for free phenytoin.
6 . The method of claim 1 , wherein the published material includes information that in a single-dose co-administration study of 12 patients,
the geometric mean of C max for free phenytoin when phenytoin was administered alone was 282.76 ng/ml, and the geometric mean of C max for free phenytoin when phenytoin was co-administered with carisoprodol was 322.25 ng/ml; and
the geometric mean of AUC 0-t for free phenytoin when phenytoin was administered alone was 5150.25 hr*ng/ml, and the geometric mean of AUC 0-t for free phenytoin when phenytoin was co-administered with carisoprodol was 5559.62 hr*ng/ml.
7 . The method of claim 5 , further comprising providing information that single-dose, co-administration of phenytoin and carisoprodol resulted in a 13% increase in the C max for total phenytoin and a 6% increase in the AUC 0-t for total phenytoin.
8 - 9 . (canceled)
10 . The method of claim 16 , wherein the free phenytoin in the serum sample from the patient is measured once every 7 to 14 days.
11 - 13 . (canceled)
14 . A method of treating a patient in need of treatment for epilepsy, comprising:
providing to a patient in need thereof a dose of phenytoin or fosphenytoin, and a dose of caridsoprodol, and
monitoring the free phenytoin concentration in a serum sample from the patient.
15 . The method of claim 14 , wherein the free phenytoin in the serum sample from the patient is measured is measured once every 7 to 14 days.
16 . A method of administering carisoprodol, comprising
co-administering to a patient carisoprodol with phenytoin or fosphenytoin, and
monitoring the free phenytoin concentration in a serum sample from the patient.
17 . The method of claim 16 , further comprising
monitoring the total phenytoin level in the serum sample from the patient.
18 . The method of claim 16 , further comprising adjusting the dosage of phenytoin or fosphenytoin in response to the monitoring.
19 - 20 . (canceled)
21 . The method of claim 14 , further comprising
monitoring the total phenytoin level in the serum sample from the patient.